Sponsor pipeline

Minovia Therapeutics Ltd. clinical trial pipeline

Get alerts when Minovia Therapeutics Ltd.'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-21

What changed in the last 30 days

2 trials changed in the last 30 days: 0 stopped, 2 with notable changes, 0 with minor changes only.

  1. Notable

    Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria · a Diagnosis of Pearson Syndrome (PS)

    Primary completion pushed from Dec 2026 to Dec 2027

    Also in this update: Study completion pushed from Dec 2027 to Dec 2028

    Minovia Therapeutics Ltd.Phase 2 NCT06017869 Registry history of NCT06017869 on ClinicalTrials.gov (opens the registry)

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1
1
Phase 2
1
Not charted: 3 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Disease areas by active trials

Get alerts when Minovia Therapeutics Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free